Skip to main content

Telomir Pharmaceuticals, Inc.

corporate_fare Company Profile

Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed TELO - Latest Insights

TELO
Apr 24, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Telomir Completes Strategic Acquisition, Consolidates IP, and Secures Up To $5M in Funding
Sentiment: Neutral
View Wiseek Article
TELO
Apr 24, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
Telomir Completes TELI Acquisition, Secures Global Rights to Lead Drug Telomir-1, Receives $1M Funding
Sentiment: Positive
View Wiseek Article
TELO
Mar 31, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Telomir Pharmaceuticals Achieves Nasdaq Compliance for Annual Meeting Requirement
Sentiment: Positive
View Wiseek Article
TELO
Mar 31, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Telomir Pharmaceuticals Submits IND for Lead Cancer Drug Telomir-1 in Triple-Negative Breast Cancer
Sentiment: Positive
View Wiseek Article
TELO
Mar 27, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
8
Telomir Shareholders Approve 5 Million Share Increase for Incentive Plan
Sentiment: Negative
View Wiseek Article
TELO
Mar 27, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Shareholders Approve Highly Dilutive Acquisition and Expanded Incentive Plan Amidst Going Concern
Sentiment: Negative
View Wiseek Article
TELO
Mar 17, 2026, 5:28 PM EDT
Filing Type: 10-K
Importance Score:
9
Telomir Pharmaceuticals Reports Going Concern Doubt, Pursues Merger & Additional Financing Amidst Significant Losses
Sentiment: Negative
View Wiseek Article
TELO
Feb 19, 2026, 5:12 PM EST
Filing Type: DEFA14A
Importance Score:
9
Telomir Pharmaceuticals Finalizes Proxy for Shareholder Vote on Transformative Reverse Merger
Sentiment: Neutral
View Wiseek Article
TELO
Feb 17, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Telomir-1 Demonstrates Broad Tumor Cell Mortality in Triple-Negative Breast Cancer Models
Sentiment: Positive
View Wiseek Article
TELO
Feb 05, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Telomir Pharmaceuticals Reports New Cellular Data for Telomir-1, Supporting Epigenetic Mechanism and Q1 2026 IND Submission
Sentiment: Positive
View Wiseek Article
TELO
Feb 04, 2026, 7:03 PM EST
Filing Type: PRER14A
Importance Score:
9
Amended Proxy Details Highly Dilutive Reverse Merger with TELI, Raises Governance Concerns
Sentiment: Negative
View Wiseek Article
TELO
Jan 23, 2026, 5:04 PM EST
Filing Type: PRER14A
Importance Score:
9
Shareholders to Vote on Highly Dilutive Reverse Merger with TELI Pharmaceuticals, Shifting Control and Increasing Equity Pool
Sentiment: Negative
View Wiseek Article
TELO
Jan 09, 2026, 7:50 PM EST
Filing Type: 8-K
Importance Score:
9
Telomir Pharmaceuticals Receives Nasdaq Non-Compliance Notice for Delayed Annual Meeting
Sentiment: Negative
View Wiseek Article
TELO
Jan 05, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Telomir-1 Shows Significant Efficacy in Preclinical Triple-Negative Breast Cancer Models
Sentiment: Positive
View Wiseek Article